CTOs on the Move

Thrasos Therapeutics

www.thrasos.com

 
Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.thrasos.com
  • 2000 Rue Peel
    Montreal, AB CAN H3A 2W5
  • Phone: 514.940.2714

Executives

Name Title Contact Details

Similar Companies

Palvella Therapeutics

Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments.

IFM Therapeutics

At IFM Therapeutics, LLC, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body`s first line of immunological response and an essential component of immune function.

J. Craig Venter Institute (JVCI)

J. Craig Venter Institute (JVCI) is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atsena Therapeutics

Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.

Xenotope Diagnostics

Xenotope Diagnostics is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.